Hybrid F-FDG-PET/MRI Measurement of Standardized Uptake Value Coupled with Yin Yang 1 Signature in Metastatic Breast Cancer. A Preliminary Study

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2019 Sep 29

PMID 31561604

Citations 15

Authors

Concetta Schiano

Monica Franzese

Katia Pane

Nunzia Garbino

Andrea Soricelli

Marco Salvatore

Filomena de Nigris

Claudio Napoli

Affiliations

Soon will be listed here.

Abstract

Purpose: Detection of breast cancer (BC) metastasis at the early stage is important for the assessment of BC progression status. Image analysis represents a valuable tool for the management of oncological patients. Our preliminary study combined imaging parameters from hybrid F-FDG-PET/MRI and the expression level of the transcriptional factor Yin Yang 1 (YY1) for the detection of early metastases.

Methods: The study enrolled suspected n = 217 BC patients that underwent F-FDG-PET/MRI scans. The analysis retrospectively included n = 55 subjects. n = 40 were BC patients and n = 15 imaging-negative female individuals were healthy subjects (HS). Standard radiomics parameters were extracted from PET/MRI image. RNA was obtained from peripheral blood mononuclear cells and YY1 expression level was evaluated by real time reverse transcription polymerase chain reactions (qRT-PCR). An enzyme-linked immuosorbent assay (ELISA) was used to determine the amount of YY1 serum protein. Statistical comparison between subgroups was evaluated by Mann-Whitney U and Spearman's tests.

Results: Radiomics showed a significant positive correlation between Greg-level co-occurrence matrix (GLCM) and standardized uptake value maximum (SUVmax) (r = 0.8 and r = 0.8 respectively) in BC patients. YY1 level was significant overexpressed in estrogen receptor (ER)-positive/progesteron receptor-positive/human epidermal growth factor receptor2-negative (ER+/PR+/HER2-) subtype of BC patients with synchronous metastasis (SM) at primary diagnosis compared to metachronous metastasis (MM) and HS (p < 0.001) and correlating significantly with F-FDG-uptake parameter (SUVmax) (r = 0.48).

Conclusions: The combination of functional F-FDG-PET/MRI parameters and molecular determination of YY1 could represent a novel integrated approach to predict synchronous metastatic disease with more accuracy than F-FDG-PET/MRI alone.

Citing Articles

Assessment of androgen receptor expression in breast cancer patients using 18 F-FDG PET/CT radiomics and clinicopathological characteristics.

Jia T, Lv Q, Zhang B, Yu C, Sang S, Deng S BMC Med Imaging. 2023; 23(1):93.

PMID: 37460990 PMC: 10353086. DOI: 10.1186/s12880-023-01052-z.

miRNA-1246, HOTAIR, and IL-39 signature as potential diagnostic biomarkers in breast cancer.

Khaliefa A, Desouky E, Hozayen W, Shaaban S, Hasona N Noncoding RNA Res. 2023; 8(2):205-210.

PMID: 36865390 PMC: 9972401. DOI: 10.1016/j.ncrna.2023.02.002.

PET-Derived Radiomics and Artificial Intelligence in Breast Cancer: A Systematic Review.

Urso L, Manco L, Castello A, Evangelista L, Guidi G, Castellani M Int J Mol Sci. 2022; 23(21).

PMID: 36362190 PMC: 9653918. DOI: 10.3390/ijms232113409.

Interrupting specific hydrogen bonds between ELF3 and MED23 as an alternative drug resistance-free strategy for HER2-overexpressing cancers.

Hwang S, Park S, Jo H, Seo S, Jeon K, Kim S J Adv Res. 2022; 47:173-187.

PMID: 35963541 PMC: 10173165. DOI: 10.1016/j.jare.2022.08.003.

Radiomics in Oncological PET Imaging: A Systematic Review-Part 1, Supradiaphragmatic Cancers.

Morland D, Triumbari E, Boldrini L, Gatta R, Pizzuto D, Annunziata S Diagnostics (Basel). 2022; 12(6).

PMID: 35741138 PMC: 9221970. DOI: 10.3390/diagnostics12061329.

References

Chinnappan D, Xiao D, Ratnasari A, Andry C, King T, Weber H . Transcription factor YY1 expression in human gastrointestinal cancer cells. Int J Oncol. 2009; 34(5):1417-23. View

Begon D, Delacroix L, Vernimmen D, Jackers P, Winkler R . Yin Yang 1 cooperates with activator protein 2 to stimulate ERBB2 gene expression in mammary cancer cells. J Biol Chem. 2005; 280(26):24428-34. DOI: 10.1074/jbc.M503790200. View

Bonavida B, Kaufhold S . Prognostic significance of YY1 protein expression and mRNA levels by bioinformatics analysis in human cancers: a therapeutic target. Pharmacol Ther. 2015; 150:149-68. DOI: 10.1016/j.pharmthera.2015.01.011. View

Baritaki S, Huerta-Yepez S, Sakai T, Spandidos D, Bonavida B . Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1. Mol Cancer Ther. 2007; 6(4):1387-99. DOI: 10.1158/1535-7163.MCT-06-0521. View

Schlemmer H, Pichler B, Krieg R, Heiss W . An integrated MR/PET system: prospective applications. Abdom Imaging. 2008; 34(6):668-74. PMC: 2774419. DOI: 10.1007/s00261-008-9450-2. View

Zaravinos A, Spandidos D . Yin yang 1 expression in human tumors. Cell Cycle. 2010; 9(3):512-22. DOI: 10.4161/cc.9.3.10588. View

Pace L, Nicolai E, Luongo A, Aiello M, Catalano O, Soricelli A . Comparison of whole-body PET/CT and PET/MRI in breast cancer patients: lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues. Eur J Radiol. 2013; 83(2):289-96. DOI: 10.1016/j.ejrad.2013.11.002. View

Allouche A, Nolens G, Tancredi A, Delacroix L, Mardaga J, Fridman V . The combined immunodetection of AP-2alpha and YY1 transcription factors is associated with ERBB2 gene overexpression in primary breast tumors. Breast Cancer Res. 2008; 10(1):R9. PMC: 2374961. DOI: 10.1186/bcr1851. View

Yang W, Feng B, Meng Y, Wang J, Geng B, Cui Q . FAM3C-YY1 axis is essential for TGFβ-promoted proliferation and migration of human breast cancer MDA-MB-231 cells via the activation of HSF1. J Cell Mol Med. 2019; 23(5):3464-3475. PMC: 6484506. DOI: 10.1111/jcmm.14243. View

10.

Bailly C, Bodet-Milin C, Bourgeois M, Gouard S, Ansquer C, Barbaud M . Exploring Tumor Heterogeneity Using PET Imaging: The Big Picture. Cancers (Basel). 2019; 11(9). PMC: 6770004. DOI: 10.3390/cancers11091282. View

11.

Kang W, Tong J, Chan A, Zhao J, Dong Y, Wang S . Yin Yang 1 contributes to gastric carcinogenesis and its nuclear expression correlates with shorter survival in patients with early stage gastric adenocarcinoma. J Transl Med. 2014; 12:80. PMC: 3986816. DOI: 10.1186/1479-5876-12-80. View

12.

de Nigris F, Botti C, De Chiara A, Rossiello R, Apice G, Fazioli F . Expression of transcription factor Yin Yang 1 in human osteosarcomas. Eur J Cancer. 2006; 42(15):2420-4. DOI: 10.1016/j.ejca.2006.06.008. View

13.

Werner M, Schmidt H, Schwenzer N . MR/PET: a new challenge in hybrid imaging. AJR Am J Roentgenol. 2012; 199(2):272-7. DOI: 10.2214/AJR.12.8724. View

14.

Zhang Q, Stovall D, Inoue K, Sui G . The oncogenic role of Yin Yang 1. Crit Rev Oncog. 2012; 16(3-4):163-97. PMC: 3386643. DOI: 10.1615/critrevoncog.v16.i3-4.30. View

15.

Grueneisen J, Sawicki L, Wetter A, Kirchner J, Kinner S, Aktas B . Evaluation of PET and MR datasets in integrated 18F-FDG PET/MRI: A comparison of different MR sequences for whole-body restaging of breast cancer patients. Eur J Radiol. 2017; 89:14-19. DOI: 10.1016/j.ejrad.2016.12.019. View

16.

Dubey I, Jain A, Chauhan M, Kumar R, Agarwal S, Kishore B . Tumor characteristics and metabolic quantification in carcinoma breast: An institutional experience. Indian J Cancer. 2017; 54(1):333-339. DOI: 10.4103/ijc.IJC_121_17. View

17.

Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C . Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52. DOI: 10.1038/35021093. View

18.

Shen X, Zhong J, Yu P, Zhao Q, Huang T . YY1-regulated LINC00152 promotes triple negative breast cancer progression by affecting on stability of PTEN protein. Biochem Biophys Res Commun. 2018; 509(2):448-454. DOI: 10.1016/j.bbrc.2018.12.074. View

19.

Groheux D, Giacchetti S, Moretti J, Porcher R, Espie M, Lehmann-Che J . Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2010; 38(3):426-35. DOI: 10.1007/s00259-010-1640-9. View

20.

Thomassen M, Tan Q, Kruse T . Gene expression meta-analysis identifies metastatic pathways and transcription factors in breast cancer. BMC Cancer. 2009; 8:394. PMC: 2642844. DOI: 10.1186/1471-2407-8-394. View